GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
- Conditions
- Incontinence, Urinary and Urinary Bladder, OveractiveOveractive Bladder
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT00321477
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer
- Conditions
- Lung Cancer, Small Cell
- Interventions
- Drug: Intravenous topotecan/cisplatinDrug: Intravenous etoposide/cisplatin
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 700
- Registration Number
- NCT00320359
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Social Anxiety Disorder Study Of Paroxetine
- Conditions
- Social Phobia
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 390
- Registration Number
- NCT00318669
- Locations
GSK Investigational Site
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
- Conditions
- Migraine DisordersMigraine
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT00319137
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- Conditions
- Non-Insulin-Dependent Diabetes Mellitus
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2009-05-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00318656
Effect Of GW501516X On How The Heart Obtains And Uses Energy
- Conditions
- DyslipidaemiasHeart Failure
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00318617
- Locations
- 🇺🇸
GSK Investigational Site, Philadelphia, Pennsylvania, United States
The Effect Of AVANDIA On The Late Asthmatic Response
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00318630
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
- Conditions
- Influenza
- Interventions
- Biological: Adjuvanted pandemic influenza candidate vaccineBiological: FluarixBiological: Placebo
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5075
- Registration Number
- NCT00319098
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
- Conditions
- Lymphoma, Small Cleaved-Cell, FollicularLymphoma, Large-Cell, FollicularLymphoma, FollicularLymphoma, Non-Hodgkin
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00319332
- Locations
- 🇺🇸
GSK Clinical Trials Call Center, Tacoma, Washington, United States
🇺🇸GSK Clinical Trial Call Center, Seattle, Washington, United States
Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population
- Conditions
- Influenza
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT00318058
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium